Onriva Trio Inhalation Capsule 150 mcg+50 mcg+160 mcg is an advanced triple-combination inhalation therapy formulated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). It contains Indacaterol, Glycopyrronium, and Mometasone Furoate, combining two long-acting bronchodilators with an inhaled corticosteroid to provide comprehensive respiratory control in patients with moderate to severe COPD.

This triple therapy is designed for adult patients who continue to experience symptoms or frequent exacerbations despite dual bronchodilator treatment. By targeting different pathways involved in airway obstruction and inflammation, Onriva Trio helps improve lung function, control symptoms, and reduce the risk of COPD exacerbations with a convenient once-daily dosing regimen.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Composition and Mechanism of Action

Indacaterol (150 mcg)

Indacaterol is a long-acting β₂-adrenergic agonist (LABA) that relaxes bronchial smooth muscle by stimulating β₂ receptors. It provides rapid onset and sustained bronchodilation for up to 24 hours, improving airflow and reducing breathlessness.

Glycopyrronium (50 mcg)

Glycopyrronium is a long-acting muscarinic antagonist (LAMA) that inhibits acetylcholine-induced bronchoconstriction by blocking muscarinic receptors in the airways. This action helps maintain open airways and complements the bronchodilatory effect of Indacaterol.

Mometasone Furoate (160 mcg)

Mometasone Furoate is a potent inhaled corticosteroid (ICS) that reduces airway inflammation, swelling, and mucus production. It plays a key role in decreasing the frequency and severity of COPD exacerbations, particularly in patients with an inflammatory component to their disease.

The combined LABA, LAMA, and ICS actions provide comprehensive and sustained respiratory control.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Benefits

• Triple-action therapy for comprehensive COPD management

• Provides sustained bronchodilation and anti-inflammatory effects

• Improves lung function and airflow

• Reduces symptoms such as shortness of breath, cough, and wheezing

• Helps lower the risk of COPD exacerbations

• Once-daily dosing improves treatment adherence and convenience

• Enhances quality of life and exercise tolerance

Indications

Onriva Trio Inhalation Capsule is indicated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, in adult patients who require triple therapy for better symptom control and exacerbation prevention. It is not intended for the relief of acute bronchospasm or for the treatment of asthma.

Dosage and Administration

• For inhalation use only

• One capsule inhaled once daily using a suitable dry powder inhaler

• Capsules must not be swallowed

• Should be used at the same time each day for consistent therapeutic benefit

Patients should be properly trained in inhaler technique to ensure optimal drug delivery to the lungs.

Safety and Precautions

• Not suitable for sudden breathing difficulties or acute COPD attacks

• A short-acting rescue inhaler should be available for emergency use

• Caution is advised in patients with cardiovascular disease, infections, glaucoma, or osteoporosis

• Rinse mouth after inhalation to reduce the risk of oral corticosteroid-related side effects

Regular follow-up and monitoring are recommended during long-term use.

Storage and Handling

Store Onriva Trio Inhalation Capsules in a cool, dry place, protected from moisture and direct sunlight. Keep capsules in the blister pack until immediately before use and keep out of reach of children.